Clinical Trials Logo

Nicotine clinical trials

View clinical trials related to Nicotine.

Filter by:

NCT ID: NCT06346353 Recruiting - Depression Clinical Trials

Substance Consumption, Personality, and Cognitive Functioning of Chess Players

Start date: January 31, 2024
Phase:
Study type: Observational

The aim of this project is to find out if there is a difference in addictive behavior, personality traits, and cognitive abilities between chess players and non-chess players.

NCT ID: NCT05864586 Recruiting - E-cigarette Use Clinical Trials

Developing E-liquid Product Standards (Sweet Spot Study)

Start date: May 30, 2023
Phase: N/A
Study type: Interventional

The Sweet Spot Study aims to evaluate the effect of e-liquids with nicotine varying in freebase (FB) levels and concentrations on the appeal of electronic cigarettes (ECs) in young adult EC users with minimal/no history of smoking and older adult smokers.

NCT ID: NCT05487456 Completed - Vaping Clinical Trials

Reduced HPHC Exposure in Cigarette Smokers Switching to P4M3 Gen. 2.0 Compared to Continuing Smoking, or Smoking Abstinence

Start date: July 15, 2022
Phase: N/A
Study type: Interventional

To demonstrate the reduction of Biomarkers of Exposure (BoExp) to selected harmful and potentially harmful constituents (HPHC) in smokers switching from cigarette (CIG) to P4M3, an Electronic Nicotine Delivery System (ENDS), compared to continuing cigarette smoking for 5 days.

NCT ID: NCT05383508 Completed - Vaping Clinical Trials

Nicotine Pharmacokinetics Following Use of the P4M3 Gen 2.0 E-Cigarette Compared to Smoking Cigarettes

Start date: April 28, 2022
Phase: N/A
Study type: Interventional

This is a single-center, randomized, controlled, open-label, cross-over study with healthy adult smokers. The study will investigate the nicotine pharmacokinetic (PK) profiles of two e-liquid variants used with the P4M3 Gen 2.0 e-cigarette, compared to smoking combustible cigarettes. In addition, pharmacodynamic (PD) effects (subjective effects and related behavioral assessments), will be evaluated to provide further insights on product evaluation, craving, liking, puffing topography. The study will be conducted with three periods and six sequences in a cross-over design. This study is exploratory and there is no pre-specified hypothesis to be tested.

NCT ID: NCT05317195 Completed - Smoking Clinical Trials

Nicotine Pharmacokinetics and Subjective Effects of Nicotine Pouch 1.0 Compared to Velo® Ice Cool and Zyn® Cool Mint Mini Dry in Healthy Smokers

Start date: March 15, 2022
Phase: N/A
Study type: Interventional

This is a single-center, randomized, controlled, open-label, cross-over study in healthy smoking subjects to investigate the nicotine pharmacokinetic (PK) profiles of 4 variants of Nicotine pouch 1.0 compared to marketed Velo - Nicotine Pouch (NP) and Zyn-NP. In addition, pharmacodynamic (PD) effects will be evaluated to provide further insights on Nicotine pouch 1.0 product acceptance and abuse liability. The study will be conducted with 3 periods and 6 sequences in a Williams design (cross-over).

NCT ID: NCT04189146 Active, not recruiting - Depression Clinical Trials

Inner Engineering Yoga Program on Short and Long Term Health Effects (ISHA-Impact): A Longitudinal Study

ISHA-Impact
Start date: March 12, 2019
Phase: N/A
Study type: Interventional

This study will include any participant who registered, and plans to attend the Inner Engineering In-Person Completion Course. In 2019, this course was offered in: Los Angeles in March, Philadelphia in April and Toronto & Dallas in November. This study has been involved in every IECO Course since 2019 and is still active today. Beginning in August 2021, investigators will recruit for the August Inner Engineering In-Person Completion Course. Investigators anticipate that this study can include up to 5,000 study participants. Participants would attend this course and complete the pre-modules regardless of whether or not they participate in this study.

NCT ID: NCT04124432 Completed - Cannabis Clinical Trials

Behavioral Pharmacology of Cannabis and Nicotine

Start date: September 15, 2020
Phase: Phase 1
Study type: Interventional

This study will evaluate the individual and interactive pharmacokinetic and pharmacodynamic effects of smoked cannabis and nicotine.

NCT ID: NCT04038515 Enrolling by invitation - Nicotine Clinical Trials

Impact of Flavors on Nicotine Perception and Self-Administration Via E-cigarettes

Start date: October 27, 2022
Phase: Phase 2
Study type: Interventional

The goal of this application is to test whether menthol and fruit flavors impact e-cigarette use through dissociable mechanisms and exert their effects differentially across nicotine doses.

NCT ID: NCT03576768 Terminated - Addiction Clinical Trials

QuitFast: Evaluating Transcranial Magnetic Stimulation as a Tool to Reduce Smoking Directly Following a Quit Attempt

Start date: September 4, 2018
Phase: N/A
Study type: Interventional

Cigarette smoking constitutes the greatest preventable cause of mortality and morbidity in the US. The most critical period for long term success of smoking cessation appears to be in the first 7 days after the quit date. A metaanalysis of 3 pharmacotherapy trials revealed that abstinence during the first 7 days was the strongest predictor of 6 month outcomes (n=1649; Odds ratio: 1.4, P <0.0001; Ashare et al. 2013). Prodigious relapse rates during this first week of smoking cessation are likely due to behavioral and neurobiological factors that contribute to high cue-associated craving and low executive control over smoking. The long term goal of the research is to develop evidence-based transcranial magnetic stimulation protocols to facilitate abstinence during this critical period.

NCT ID: NCT03134339 Completed - Nicotine Clinical Trials

The Effect of Nicotine Delivery Rate on Reinforcement

Start date: January 5, 2017
Phase: Early Phase 1
Study type: Interventional

The dose-effect curve to estimate a threshold delivery rate for reinforcement. The project addresses the FDA Center for Tobacco Products (CTP) interest #1: Nicotine dependence threshold among youth and adults and impact of nicotine reduction on tobacco product use behavior (e.g., topography, compensation, switching, multiple use, initiation, cessation and relapse). IV nicotine, in contrast to ECs, can deliver precise, reproducible dosing, which is necessary for accurately assessing dose-response and threshold effects. The estimated threshold for reinforcement will establish a benchmark for evaluating the addictive potential of ECs and other inhaled nicotine products.